


Supplemental Figure 1. Flow cytometry analysis of HIV-specific CD8 T cells before and after IL-7 therapy. Gating strategy for flow cytometry is shown in (A). The change in frequency of HIV-specific CD8 T cells is plotted against the change in CD4 counts (B) and the change in the cellular activation as measured by the frequency of CD38⁺ cells (C). The frequencies of IL-7R⁺ HIV-specific T cells (D). The frequency of PD-1⁺ (E) or TIM3⁺ (F) HIV-specific CD8 T cells are plotted against cellular activation as measured by the frequency of CD38⁺ cells. Linear regression is shown for baseline (solid line) and week 12 (dotted line). The frequencies of IFN γ and IL-2⁺ CD8 T cells in response to HIV-peptide as compared to no-peptide are reported for TRAF1_{INC} and TRAF1_{DEC} T cell populations at baseline and wk12 (G). Left: representative flow cytometry plots; right summary panels. Statistical analysis was performed as described in materials and methods.



Supplemental Figure 2. TRAF1, Erk and pS6 levels before and after IL-7 therapy. The median fluorescent intensity (MFI) of pS6 in pS6⁺ CD45RA⁻ total CD8 T cells is reported in (A). The frequency of TRAF1⁺ cells is plotted against the frequency of pErk⁺pS6⁺ HIV-specific CD8 T cells (B). The frequency of TRAF1⁺ cells among the CD45RA⁻ CD8 T cell population is plotted against the frequency of pErk⁺pS6⁺ CD45RA⁻ CD8 T cells ((C). The level of TRAF1 as measured by MFI (D) is plotted for pS6⁻ and pS6⁺ HIV-specific CD8 T cells before and after IL-7 treatment. (E) the dMFI of pS6 is plotted against dMFI of pErk. (F) The size of cells as measured by forward scatter is plotted for pS6⁻ and pS6⁺ HIV specific CD8 T cells before and after IL-7 treatment.